亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)

医学 表皮生长因子受体 外显子 酪氨酸激酶 癌症研究 肺癌 不利影响 突变 癌症 受体 表皮生长因子 吉非替尼 酪氨酸激酶抑制剂 激酶 受体酪氨酸激酶 临床研究阶段 内科学 细胞生长 T790米 分子生物学 生长因子受体 ERBB3型 血小板源性生长因子受体 细胞培养 肺 细胞 表皮生长因子受体抑制剂 基因
作者
James Chih‐Hsin Yang,Mengzhao Wang,Ludovic Doucet,Yun Fan,Dongqing Lv,Meili Sun,Dingzhi Huang,Laurent Greillier,David Planchard,Qunying Hong,Julien Mazières,Enriqueta Felip,Xingya Li,Ying Hu,Jian Fang,Lyudmila A. Bazhenova,François Ghiringhelli,Manuel Angel Cobo Dols,Luis Paz-Ares Rodriguez,Alessandra Bearz
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (29): 3198-3208 被引量:35
标识
DOI:10.1200/jco-25-00788
摘要

PURPOSE WU-KONG1B (ClinicalTrials.gov identifier: NCT03974022 ) is a multinational phase II, dose-randomized study to assess the antitumor efficacy of sunvozertinib in pretreated patients with advanced non–small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) exon 20 insertion mutations (exon20ins). METHODS Eligible patients with advanced-stage EGFR exon20ins NSCLC were randomly assigned by 1:1 ratio to receive sunvozertinib 200 mg or 300 mg once daily (200 and 300 mg-rand cohorts). After predefined interim analysis, additional patients were enrolled and treated with the 300 mg dose once daily. The primary end point was blinded independent review committee (IRC)–assessed confirmed objective response rate (cORR), and the key secondary end point was duration of response (DoR). RESULTS Among 85, 89, and 107 efficacy-evaluable patients in 200 mg-rand, 300 mg-rand, and 300 mg-all (including randomly assigned and nonrandomized patients) cohorts, the cORRs were 45.9% (97.5% CI, 33.6% to 58.5%), 47.2% (97.5% CI, 35.1% to 59.5%), and 45.8% (97.5% CI, 34.8% to 57.0%), respectively, per IRC assessment. The predefined null hypothesis was rejected with statistical significance ( P < .0001). Comparing 300 and 200 mg-rand cohorts, higher cORRs were observed in patients with baseline brain metastasis (52.4% v 28.6%) and previous amivantamab treatment (41.7% v 25%), as well as longer DoR (13.8 v 11.1 months). At 200 and 300 mg once daily, the most common treatment-related adverse events with grade ≥3 included diarrhea (2.2% v 18%), blood creatine phosphokinase increased (6.6% v 12.6%), and anemia (4.4% v 6.3%). CONCLUSION Sunvozertinib is efficacious at both 200 and 300 mg once daily in treating platinum-pretreated patients with advanced EGFR exon20ins NSCLC. The treatment-related adverse events of sunvozertinib were consistent with an EGFR tyrosine kinase inhibitor, with a more favorable safety profile at 200 mg than 300 mg once daily.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
7秒前
liugm发布了新的文献求助10
8秒前
toxin37完成签到 ,获得积分10
10秒前
小井盖完成签到 ,获得积分0
11秒前
12秒前
含蓄的芝麻完成签到,获得积分10
13秒前
陌陌完成签到 ,获得积分10
14秒前
菌菌的应助被郦稀采纳,获得30
17秒前
20秒前
煊陌完成签到 ,获得积分10
23秒前
xiaoyin完成签到 ,获得积分10
24秒前
25秒前
25秒前
Lifel完成签到,获得积分10
25秒前
32秒前
34秒前
A水暖五金批发张哥完成签到,获得积分10
34秒前
Ni完成签到 ,获得积分10
35秒前
云墨完成签到 ,获得积分10
35秒前
36秒前
椰子云发布了新的文献求助10
38秒前
学术雷锋发布了新的文献求助10
41秒前
Moon完成签到 ,获得积分10
45秒前
天真的乐驹完成签到 ,获得积分10
49秒前
李健的小迷弟的应助被郦稀采纳,获得10
49秒前
Moon关注了科研通微信公众号
49秒前
50秒前
乐康完成签到,获得积分10
50秒前
53秒前
复杂惜珊完成签到,获得积分10
1分钟前
cx完成签到,获得积分10
1分钟前
机灵伟诚完成签到,获得积分10
1分钟前
学霸业的应助被纯情的阁采纳,获得10
1分钟前
极限001的应助被纯情的阁采纳,获得50
1分钟前
Maestro_S的应助被纯情的阁采纳,获得10
1分钟前
Nikkie2411的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
1分钟前
369ninja的应助被科研通管家采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277